News

News 19.02.2018 Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that Allergan has exercised the third option to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners. Upon the exercise of this option,...

News 08.01.2018 Kuros announced that it has amended its exclusive license agreement, which was originally signed in 2015, that grants Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) access to Kuros’ clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis. The amendment extends the field...

News 08.01.2018 Molecular Partners AG announced initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (MM). Eight patients have been treated in the first cohort of 8 mg/kg MP0250 and were included in the safety analysis set. No dose-limiting toxicities (DLTs) have been reported to date....

News 07.01.2018 Molecular Partners AG announced that Allergan has exercised two options to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners. Upon receipt of approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, Molecular Partners will grant Allergan an exclusive license to the...

News 09.11.2017 Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd. focused on the development of human antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration agreement Neurimmune...